Fig. 2

CCL7 promoted recruitment of early OCPs. A, B Flow cytometry analysis revealed percentage of CD115(+) early OCPs in bone marrow at 10 days post injection of MC-38 with treatment of CCL7 nAb or vehicle (A) and quantification of percentage of early OCPs (B). n = 4, each sample was pooled from 5 mice. C, D Flow cytometry analysis showed the BrdU incorporation in early OCPs treated by recombinant CCL7 or vehicle in the presence of MC-38 CM (C) and quantification of BrdU incorporation in early OCPs (D). n = 5. E, F Annexin V/PI analysis showed the apoptotic early OCPs treated by recombinant CCL7 or vehicle in the presence of MC-38 CM (E) and quantification of apoptosis of early OCPs (F). n = 4. G, H TRAP staining showed OCs after treated with CCL7 or vehicle in the presence of M-CSF (50 ng/mL) and RANKL (100 ng/mL) for 4 days (G) and quantification of OCs per field (H). n = 6. I, J Transwell analysis showed migration of early OCPs treated by CCL7 for 12 h (I) and quantification of migration number of early OCPs (J). n = 6. K Quantification of I using Absorbency analysis. n = 4. L qRT-PCR analysis detected mRNA level of CCL7 in neutrophils, eosinophils, T cells, BMMSCs and early OCPs isolated from 10 days post injection of MC-38 compared to that in MC-38 cells. n = 3, each sample was pooled from 5 to 8 mice. **p < 0.01, ***p < 0.001